Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Researchers identified novel oncogenic function for receptor linked to Alzheimer's disease

Common and rare SORLA single nucleotide polymorphisms have been associated with the development of Alzheimer's disease.

So far, SORLA has been mainly studied in neurons, but the new study focused on SORLA's role in cancer cells. 

Led by Academy Professor Johanna Ivaska, researchers from the University of Turku in Finland observed that SORLA was highly expressed in HER2 positive cancers.

Removing SORLA from cancer cells severely impaired the oncogenic fitness of HER2 positive cancers.

HER2 is a strong driver of tumour growth.

HER2 amplification occurs in about 20% of breast cancers and over expression or amplification of HER2 is also commonly found in bladder and gastric cancers.

HER2 targeting therapies, such as Herceptin, are widely used in clinics and it plays an important role in the treatment of HER2 positive cancers.

However, some patients will eventually progress during the Herceptin treatment and some do not respond to it at all.

The newly discovered role of SORLA in regulating the oncogenic fitness of HER2 offers novel possibilities to target HER2 positive cancers in the future.

"Our study showed that removing the SORLA protein from HER2 positive cancer cell lines, from which some were sensitive and some resistant to Herceptin, strongly inhibited the in vitro proliferation of these cells. More importantly, removing the SORLA protein from these cells prevented tumour formation and growth in mice. So far, the role of SORLA in cancer has been unknown, and our discovery on HER2 positive cancers being dependent on SORLA was surprising, since this cancer type has already been widely studied," says former Ivaska Lab member and Postdoctoral Researcher Mika Pietilä, who is the main author of the paper.

In vitro cell culture experiments showed that the SORLA protein promotes the recycling of the HER2 receptor back to the plasma membrane where the receptor is active and drives the proliferation of cancer cells.

When SORLA was removed, the HER2 receptor accumulated into lysosomes where the receptor is not functional and thus cannot drive the tumour growth anymore.

Previous studies have shown inverse association between Alzheimer's disease and cancer

In neurons, SORLA prevents the formation of amyloid plaques, and, therefore, inactivating or truncating mutations in SORLA are associated with the development of Alzheimer's disease.

Even though both Alzheimer's disease and cancer are common among the ageing population, previous studies have demonstrated that patients with Alzheimer's disease have a lower risk to get cancer during their lives, and, vice versa, cancer survivors have a lower risk to develop Alzheimer's disease.

"No clear reason has been found yet for the inverse association between Alzheimer's disease and cancer. Our results, which show that SORLA promotes the aggressiveness of certain cancer types, could be one factor among others in this phenomenon," suggests Ivaska.

The Ivaska Lab is located at the Turku Bio science Centre that is operated by both the University of Turku and Åbo Akademi University.

The next goal is to find a way to block the function of SORLA in tumour cells and thus develop SORLA targeting treatment.

This part of the study is already running and funded by the ERC Proof of Concept funding.

The study is also funded by the Cancer Foundation Finland's Pink Ribbon Campaign.

The study was published in the high-ranking journal Nature Communications.

Source: University of Turku

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation